CS
HZNP

Credit Suisse’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Credit Suisse’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,500
Closed -$274K – 4790
2021
Q3 		$274K Hold
2,500
– – ﹤0.01% 4119
2021
Q2 		$234K Buy
+2,500
New +$230K ﹤0.01% 4217
2021
Q1 		– Sell
-8,200
Closed -$600K – 4729
2020
Q4 		$600K Buy
+8,200
New +$610K ﹤0.01% 3696

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Credit Suisse's HZNP Position: Q4 2023 in Review

Credit Suisse sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 327,898 shares — an estimated $37.9M sold.

Credit Suisse first reported a position in HZNP in Q2 2013 and held it in 40 quarters. The position peaked at $43.8M in Q4 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Credit Suisse reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 327,898 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $37.9M.
  • Credit Suisse first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 40 quarters.
  • Credit Suisse's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $43.8M in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.